6 Citations (Scopus)

Abstract

The use of colony-stimulating factors has now become standard practice for most patients undergoing high-dose chemotherapy and autologous bone marrow or peripheral stem cell transplantation. However, the following questions, among others, remain unanswered: Which growth factor or combination of growth factors will allow for the fastest engraftment after transplantation? What is the best mode of administration and dosage for the various factors? And, most important, will the use of colony-stimulating factors allow us to cure more patients of their malignancy? These questions must be answered in controlled clinical trials so that we might best use the resources available for the patient's ultimate benefit.

Original languageEnglish (US)
Pages (from-to)261-262
Number of pages2
JournalAnnals of internal medicine
Volume116
Issue number3
DOIs
StatePublished - Jan 1 1992

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Colony-Stimulating Factors
Intercellular Signaling Peptides and Proteins
Peripheral Blood Stem Cell Transplantation
Controlled Clinical Trials
Transplantation
Bone Marrow
Drug Therapy
Neoplasms

Keywords

  • Bone marrow transplantation
  • Granulocyte-macrophage colony-stimulating factor
  • Neutropenia
  • Stem cells
  • Transplantation, autologous

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{3e19606359e64dd9ad43075f53f7609a,
title = "Granulocyte-macrophage colony-stimulating factor (GM-CSF): Answers or more questions?",
abstract = "The use of colony-stimulating factors has now become standard practice for most patients undergoing high-dose chemotherapy and autologous bone marrow or peripheral stem cell transplantation. However, the following questions, among others, remain unanswered: Which growth factor or combination of growth factors will allow for the fastest engraftment after transplantation? What is the best mode of administration and dosage for the various factors? And, most important, will the use of colony-stimulating factors allow us to cure more patients of their malignancy? These questions must be answered in controlled clinical trials so that we might best use the resources available for the patient's ultimate benefit.",
keywords = "Bone marrow transplantation, Granulocyte-macrophage colony-stimulating factor, Neutropenia, Stem cells, Transplantation, autologous",
author = "Vose, {Julie Marie} and Bierman, {Philip Jay} and Armitage, {James Olen}",
year = "1992",
month = "1",
day = "1",
doi = "10.7326/0003-4819-116-3-261",
language = "English (US)",
volume = "116",
pages = "261--262",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Granulocyte-macrophage colony-stimulating factor (GM-CSF)

T2 - Answers or more questions?

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Armitage, James Olen

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The use of colony-stimulating factors has now become standard practice for most patients undergoing high-dose chemotherapy and autologous bone marrow or peripheral stem cell transplantation. However, the following questions, among others, remain unanswered: Which growth factor or combination of growth factors will allow for the fastest engraftment after transplantation? What is the best mode of administration and dosage for the various factors? And, most important, will the use of colony-stimulating factors allow us to cure more patients of their malignancy? These questions must be answered in controlled clinical trials so that we might best use the resources available for the patient's ultimate benefit.

AB - The use of colony-stimulating factors has now become standard practice for most patients undergoing high-dose chemotherapy and autologous bone marrow or peripheral stem cell transplantation. However, the following questions, among others, remain unanswered: Which growth factor or combination of growth factors will allow for the fastest engraftment after transplantation? What is the best mode of administration and dosage for the various factors? And, most important, will the use of colony-stimulating factors allow us to cure more patients of their malignancy? These questions must be answered in controlled clinical trials so that we might best use the resources available for the patient's ultimate benefit.

KW - Bone marrow transplantation

KW - Granulocyte-macrophage colony-stimulating factor

KW - Neutropenia

KW - Stem cells

KW - Transplantation, autologous

UR - http://www.scopus.com/inward/record.url?scp=0026541485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026541485&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-116-3-261

DO - 10.7326/0003-4819-116-3-261

M3 - Editorial

VL - 116

SP - 261

EP - 262

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -